| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Argos Therapeutics (ARGS) | Piper Jaffray/ Stifel/ JMP Securities | $60.00 | n.a. | |||
| Dicerna Pharmaceuticals (DRNA) | Jefferies/ Leerink Swann/ Stifel | $69.00 | n.a. | |||
| Eleven Biotherapeutics (EBIO) | Citigroup/ Cowen and Company/ Leerink Swann | $69.00 | n.a. | |||
| Fortress Transportation and Infrastructure Investors Ltd. (TBA) | Barclays/ Deutsche Bank Securities | $100.00 | n.a. | |||
| IMS Health Holdings (IMS) | J.P. Morgan/ Goldman Sachs/ Morgan Stanley | $100.00 | n.a. | |||
| Revance Therapeutics (RVNC) | Cowen and Company/ Piper Jaffray | $86.25 | n.a. | |||
| uniQure B.V. (QURE) | Jefferies/ Leerink Swann | $75.00 | n.a. | |||
| n.a. (not available) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| None | ||||||
| New Terms | ||||||
| Acucela (TBA) | Mitsubishi UFJ/ Morgan Stanley Securities Co., Ltd. | 9.20 | $15.00 | $18.00 | $151.80 | (*) |
| (*) These shares will be offered in Japan and to investors located in jurisdictions other than the United States. Its | ||||||
| common stock is expected to be listed on the Mothers market of the Tokyo Stock Exchange. | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Dec. 30, 2013 | Manager(s) | Offered | Raised | Price | 1/3/14 | Change |
| None | ||||||
